BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31639198)

  • 1. Quality-of-life assessment in French patients with metastatic melanoma in real life.
    Kandel M; Dalle S; Bardet A; Allayous C; Mortier L; Dutriaux C; Guillot B; Leccia MT; Dalac S; Legoupil D; Saiag P; Montaudie H; Arnault JP; Brunet-Possenti F; Grob JJ; DeQuatrebarbes J; Beylot-Barry M; Lesimple T; Aubin F; Maubec E; Granel-Brocard F; Stoebner PE; Dupuy A; Dreno B; Michiels S; Lebbe C; Borget I
    Cancer; 2020 Feb; 126(3):611-618. PubMed ID: 31639198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
    Vallet A; Oriano B; Mortier L; Dalle S; Dutriaux C; Guillot B; Leccia MT; Dalac S; Saiag P; Lacour JP; Legoupil D; De Quatrebarbes J; Brunet-Possenti F; Lesimple T; Arnault JP; Aubin F; Granel-Brocard F; Stoebner PE; Maubec E; Dreno B; Allayous C; Porcher R; Lebbé C;
    JAMA Dermatol; 2019 Jun; 155(6):673-678. PubMed ID: 31042256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
    Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
    Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
    Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
    J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
    Tétu P; Allayous C; Oriano B; Dalle S; Mortier L; Leccia MT; Guillot B; Dalac S; Dutriaux C; Lacour JP; Saiag P; Brunet-Possenti F; De Quatrebarbes J; Stoebner PE; Legoupil D; Beylot-Barry M; Lesimple T; Aubin F; Dreno B; Mohamed S; Ballon A; Porcher R; Lebbe C
    Eur J Cancer; 2019 May; 112():38-46. PubMed ID: 30909072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
    Joseph RW; Liu FX; Shillington AC; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Saretsky TL; Pickard AS
    Qual Life Res; 2020 Oct; 29(10):2651-2660. PubMed ID: 32405921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life is maintained using Gamma Knife radiosurgery: a prospective study of a brain metastases patient cohort.
    Skeie BS; Eide GE; Flatebø M; Heggdal JI; Larsen E; Bragstad S; Pedersen PH; Enger PØ
    J Neurosurg; 2017 Mar; 126(3):708-725. PubMed ID: 27058206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
    Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
    Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
    Perier-Muzet M; Gatt E; Péron J; Falandry C; Amini-Adlé M; Thomas L; Dalle S; Boespflug A
    JAMA Dermatol; 2018 Jan; 154(1):82-87. PubMed ID: 29214290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data
    Di Filippo Y; Dalle S; Mortier L; Dereure O; Dalac S; Dutriaux C; Leccia MT; Legoupil D; Saiag P; Brunet-Possenti F; Arnnault JP; Maubec E; Granel-Brocard F; De Quatrebarbes J; Aubin F; Lesimple T; Beylot-Barry M; Stoebner PE; Dupuy A; Stephan A; Grob JJ; Lefevre W; Oriano B; Allayous C; Lebbé C; Montaudié H
    Ann Oncol; 2021 Apr; 32(4):542-551. PubMed ID: 33385520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and outcomes in patients with advanced melanoma in France.
    Bedane C; Leccia MT; Sassolas B; Bregman B; Lebbé C;
    Curr Med Res Opin; 2013 Oct; 29(10):1297-305. PubMed ID: 23808961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials.
    Kaufman HL; Andtbacka RHI; Collichio FA; Wolf M; Zhao Z; Shilkrut M; Puzanov I; Ross M
    J Immunother Cancer; 2017 Sep; 5(1):72. PubMed ID: 28923101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine.
    Cohen L; Parker PA; Sterner J; De Moor C
    Melanoma Res; 2002 Oct; 12(5):505-11. PubMed ID: 12394193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
    Moyers JT; Patel A; Shih W; Nagaraj G
    JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life in patients with melanoma expressed as utilities and disability weights.
    Tromme I; Devleesschauwer B; Beutels P; Richez P; Leroy A; Baurain JF; Cornelis F; Bertrand C; Legrand N; Degueldre J; Thomas L; Legrand C; Lambert J; Haagsma J; Speybroeck N
    Br J Dermatol; 2014 Dec; 171(6):1443-50. PubMed ID: 25039853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.